Latest News and Press Releases

Vertero doses first Parkinson’s patient in Phase 1b study of VT-5006, a gut-selective therapy targeting disease progression.

Brett Favre posted that he is being treated with Zhittya Genesis Medicine Inc FGF-1 in a Medical Research Study on X to improve his Parkinson's disease

A new research project aims to develop the world’s first therapy to eliminate and prevent the spread of a toxic brain protein that drives Parkinson’s disease. Innovation Fund Denmark has invested DKK...

PRI-101 inhibited aggregation of α-synuclein and actively disassembled fibrils across in vitro and in vivo models relevant to Parkinson’s disease Dusseldorf, Germany, March 19, 2026 - Priavoid GmbH...

MENLO PARK, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- SPARK NS today announced the nine projects and principal investigators selected for the SPARK NS Translational Research Program, 2026 Cohort....

SPARK NS and Haukeland University Hospital Announce Clinical Trial of D-Serine for Modifying Parkinson’s Disease Progression

Vertero strengthens Board of Directors with Independent Chair R. Scott Greer, life sciences veteran, experienced executive, investor, and advisor.

Vertero appointed 5 globally recognized leaders to its Scientific Advisory Board, strengthening the company’s mission to advance innovative therapies.

Vertero appoints Jeffrey Kasten as Chief Business Officer to drive strategic partnerships and accelerate portfolio strategy in neurodegenerative diseases.

Vertero announces initiation of Phase 1 study of VT-5006, a first-in-class selective small molecule therapy for Parkinson’s disease.